Safety Study of Avastin Used as Adjunctive Therapy in Pterygium Surgery
Part of paid clinical trials in Houston, Texas.
- Sponsor
- The University of Texas Health Science Center, Houston
- Study ID
- NCT01115517
- Phase
- PHASE2
- Status
- Completed
Conditions
- Pterygium
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 80 Years
- Healthy Volunteers
- Accepted
Interventions
- Bevacizumab — DRUG1.25 mg/mL applied one time intraoperatively using bevacizumab-soaked filter paper manually applied to bare sclera during pterygium surgery for 2 minutes, followed by copious rinsing with balanced salt solution.
- Mitomycin C — DRUGMitomycin C 0.02% will be applied to bare sclera during pterygium surgery using a medication-soaked filter paper for a duration of two minutes. After medication administration, the ocular surface will be copiously irrigated with balanced salt solution.
Study Details
This study will evaluate the efficacy and safety of the use of bevacizumab (Avastin) as an adjunctive medication during pterygium surgery in preventing pterygium recurrence. A pterygium is a white fleshy growth on the surface of the eye, which can be removed surgically. However, after surgical removal, pterygia can recur. One way of minimizing recurrence is by applying a medication called mitomycin C to the surface of the eye during pterygium surgery. However, mitomycin is associated with certain side effects, such as thinning of the eye wall and poor wound healing. Bevacizumab has a different mechanism of action and there is some evidence that it may be useful in preventing pterygium recurrence. In this study, the safety and efficacy of adjunctive intraoperative use of bevacizumab and mitomycin C for preventing pterygium recurrence will be directly compared.
Key Dates
- First listed
- May 4, 2010
- Start date
- Oct 31, 2010
- Status verified
- Sep 2016
- Primary completion
- Jul 31, 2015
- Completion
- Jul 31, 2015
Study Design
- Enrollment
- 51 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Bevacizumab
- Active Comparator: Mitomycin C
Primary Outcome Measure
Number of Participants Who Had Recurrence of Pterygia up to 1 Year [ Time Frame: 1 year ]
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Lyndon B. Johnson General Hospital | Houston | Texas | 77026 | - |
| Robert Cizik Eye Clinic | Houston | Texas | 77030 | - |